Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus
Primary Purpose
Diabetes Mellitus Type 2
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
EGT0001442
Placebo capsules to match EGT0001442
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus Type 2 focused on measuring Diabetes Mellitus Type 2
Eligibility Criteria
Inclusion Criteria:
- Male or female between the ages of 18 and 70 years diagnosed with type 2 diabetes.
- Body mass index (BMI) between 18 kg/m2 and 37 kg/m2 (inclusive).
- HbA1c levels between 6.5 and 9.5 (inclusive) where the upper limit of normal for the HbA1c assay is 6.4% or HbA1c levels between 6.2 and 9.5% (inclusive) where the upper limit of normal for the HbA1c assay is 6.1%.
- Fasting plasma glucose levels between 126 and 270 mg/dL (7 - 15 mmol/L, inclusive) while on diabetic medications.
- Treatment naïve subjects with HbA1c between 6.5 and 9.5 and fasting plasma glucose between 126 and 270 mg/dL (7 - 15 mmol/L).
- If taking drugs for diabetes, must be medically able and willing to discontinue diabetic medications for the duration of the study.
- Female subjects must be surgically sterilized or postmenopausal.
Exclusion Criteria:
- Type 1 diabetes or diabetes treated with insulin injection.
- Insulin therapy or oral antidiabetic medication other than metformin, sitagliptin, saxagliptin, a sulfonylurea or combination of these.
- Sitting blood pressure above 150/95 mmHg on two evaluations at least 10 minutes apart at screening.
- Positive results on screen for drugs of abuse.
- Previous treatment with an investigational drug within 30 days or 7 half-lives, whichever is longer.
- Previous treatment with EGT0001474 or EGT0001442.
Sites / Locations
- Research Site #10
- Research Site #04
- Research Site #12
- Research Site #07
- Research Site #08
- Research Site #06
- Research Site #11
- Research Site #01
- Research Site #15
- Research Site #03
- Research Site #13
- Research Site #02
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
EGT0001442
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Changes in Fasting Plasma Glucose (FPG) From Baseline at Week 4 for Segment 2 of the Study
Fasting glucose levels were measured at four time points; At day -2, day 1, day 27 and day 29 (24-h after the last dose). Baseline is defined as the mean of FPG values on day -2 and day 1. End of treatment is defined as the mean of FPG values on day 27 and day 29. Changes in the FPG during the study period was calculated by subtracting the Baseline FPG from End of Treatment FPG.
Pharmacokinetics of EGT0001442 (Cmax) at 4 Dose Levels at Week 4
Blood samples were collected during Segment 1 at pre-dose and at 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12 and 24 h (day 2), and 48 h (day 3) post dose for the determination of EGT0001442. Plasma concentrations of EGT0001442 were measured using a validated HPLC/MS-MS method and PK parameters were calculated by standard noncompartmental methods.
Pharmacokinetics of EGT0001442 (AUC 0-t and 0-24) at 4 Dose Levels at Week 4
Blood samples were collected during Segment 1 at pre-dose and at 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12 and 24 h (day 2), and 48 h (day 3) post dose for the determination of EGT0001442. Plasma concentrations of EGT0001442 were measured using a validated HPLC/MS-MS method and PK parameters were calculated by standard noncompartmental methods.
Secondary Outcome Measures
Change in the Body Weight From Baseline at Week 4
Changes in the body weight during the study period was calculated by subtracting body weight on day 1 from body weight at the end of treatment on day 29.
Changes in Hemoglobin A1c (HbA1c) From Baseline at Week 4
HbA1c levels were measured at two time points; on day 1 and day 29 (end of treatment). Changes in the HbA1c level during the study period was calculated by subtracting HbA1c level on day 1 from HbA1c level at the end of treatment (day 29)
Change in Urinary Glucose Excretion From Baseline to Day 1 and Day 28
Urinary glucose levels were measured at three time points; on Day 0 (baseline), Day 1 and Day 28 (end of treatment). Changes in the urinary glucose level during the study period was calculated by reducing the baseline urinary glucose level (Day 1) from urinary glucose level at end of treatment (Day 28) (i.e urinary glucose level on Day 28 minus urinary glucose level on Day 1).
Change in FPG Following Cessation of Treatment
The mean change in FPG following cessation of treatment was obtained by calculating the difference between FPG values obtained on End of treatment (average of FPG values on days 27 and 29) and on Post Treatment (average of FPG values on days 41 and 43).
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01029704
Brief Title
Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus
Official Title
A Phase II, Four-week, Multi-center, Double-blind, Placebo-controlled Parallel Group Study to Evaluate the Safety and Efficacy of EGT0001442 in Subjects With Type 2 Diabetes Mellitus With an Ascending Dose Safety and Pharmacokinetic Evaluation Period
Study Type
Interventional
2. Study Status
Record Verification Date
June 2021
Overall Recruitment Status
Completed
Study Start Date
December 2009 (Actual)
Primary Completion Date
July 2010 (Actual)
Study Completion Date
July 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Theracos
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study was to assess the effect of EGT0001442 on fasting plasma glucose after 28 days of treatment in subjects with type 2 diabetes.
The study also assessed the pharmacokinetics, safety and tolerability of EGT0001442, the effect on weight and HbA1c as well as the effect EGT0001442 has on the amount of glucose produced in the body by the urine.
Detailed Description
This was a phase 2 study to evaluate the efficacy of
EGT0001442. The study included two segments:
Segment 1 was a single center, open labeled, ascending dose study in 4 groups of 5 diabetic subjects per group who received 5, 10, 20, or 50 mg of EGT0001442 capsules orally once daily for 28 days. The subjects were in clinic for the first 3 days for safety and PK evaluation.
Segment 2 was a multi-center, double-blind, placebo-controlled parallel group study. One hundred and thirty one subjects in 5 parallel groups of approximately 25 diabetic subjects per group were randomly assigned to receive oral EGT0001442 at 5, 10, 20, or 50 mg/day or placebo once daily for 28 days in an outpatient setting.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus Type 2
Keywords
Diabetes Mellitus Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
151 (Actual)
8. Arms, Groups, and Interventions
Arm Title
EGT0001442
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
EGT0001442
Other Intervention Name(s)
Human SGLT2 inhibitor
Intervention Description
Segment 1 is a single center, open labeled, ascending dose study in diabetic subjects who will receive 5, 10, 20, or 50 mg of EGT0001442 capsules orally once daily for 28 days.
Segment 2 is a multi-center, double-blind, placebo-controlled parallel group study. Diabetic subjects will be randomly assigned to receive oral EGT0001442 at 5, 10, 20, or 50 mg/day for 28 days.
Intervention Type
Drug
Intervention Name(s)
Placebo capsules to match EGT0001442
Other Intervention Name(s)
Human SGLT2 inhibitor
Intervention Description
Segment 1: Not applicable.
Segment 2: Diabetic subjects will be randomly assigned to receive oral placebo once daily for 28 days.
Primary Outcome Measure Information:
Title
Changes in Fasting Plasma Glucose (FPG) From Baseline at Week 4 for Segment 2 of the Study
Description
Fasting glucose levels were measured at four time points; At day -2, day 1, day 27 and day 29 (24-h after the last dose). Baseline is defined as the mean of FPG values on day -2 and day 1. End of treatment is defined as the mean of FPG values on day 27 and day 29. Changes in the FPG during the study period was calculated by subtracting the Baseline FPG from End of Treatment FPG.
Time Frame
Baseline; Day -2 and Day 1. End of Treatment: Day 27 and Day 29
Title
Pharmacokinetics of EGT0001442 (Cmax) at 4 Dose Levels at Week 4
Description
Blood samples were collected during Segment 1 at pre-dose and at 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12 and 24 h (day 2), and 48 h (day 3) post dose for the determination of EGT0001442. Plasma concentrations of EGT0001442 were measured using a validated HPLC/MS-MS method and PK parameters were calculated by standard noncompartmental methods.
Time Frame
Pre-dose to 48 h post-dose
Title
Pharmacokinetics of EGT0001442 (AUC 0-t and 0-24) at 4 Dose Levels at Week 4
Description
Blood samples were collected during Segment 1 at pre-dose and at 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12 and 24 h (day 2), and 48 h (day 3) post dose for the determination of EGT0001442. Plasma concentrations of EGT0001442 were measured using a validated HPLC/MS-MS method and PK parameters were calculated by standard noncompartmental methods.
Time Frame
Pre-dose to 48 h post-dose
Secondary Outcome Measure Information:
Title
Change in the Body Weight From Baseline at Week 4
Description
Changes in the body weight during the study period was calculated by subtracting body weight on day 1 from body weight at the end of treatment on day 29.
Time Frame
Baseline and Day 29
Title
Changes in Hemoglobin A1c (HbA1c) From Baseline at Week 4
Description
HbA1c levels were measured at two time points; on day 1 and day 29 (end of treatment). Changes in the HbA1c level during the study period was calculated by subtracting HbA1c level on day 1 from HbA1c level at the end of treatment (day 29)
Time Frame
Baseline and Day 29
Title
Change in Urinary Glucose Excretion From Baseline to Day 1 and Day 28
Description
Urinary glucose levels were measured at three time points; on Day 0 (baseline), Day 1 and Day 28 (end of treatment). Changes in the urinary glucose level during the study period was calculated by reducing the baseline urinary glucose level (Day 1) from urinary glucose level at end of treatment (Day 28) (i.e urinary glucose level on Day 28 minus urinary glucose level on Day 1).
Time Frame
Baseline, Day 1 and Day 28
Title
Change in FPG Following Cessation of Treatment
Description
The mean change in FPG following cessation of treatment was obtained by calculating the difference between FPG values obtained on End of treatment (average of FPG values on days 27 and 29) and on Post Treatment (average of FPG values on days 41 and 43).
Time Frame
Days 27/29 to Days 41/43
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female between the ages of 18 and 70 years diagnosed with type 2 diabetes.
Body mass index (BMI) between 18 kg/m2 and 37 kg/m2 (inclusive).
HbA1c levels between 6.5 and 9.5 (inclusive) where the upper limit of normal for the HbA1c assay is 6.4% or HbA1c levels between 6.2 and 9.5% (inclusive) where the upper limit of normal for the HbA1c assay is 6.1%.
Fasting plasma glucose levels between 126 and 270 mg/dL (7 - 15 mmol/L, inclusive) while on diabetic medications.
Treatment naïve subjects with HbA1c between 6.5 and 9.5 and fasting plasma glucose between 126 and 270 mg/dL (7 - 15 mmol/L).
If taking drugs for diabetes, must be medically able and willing to discontinue diabetic medications for the duration of the study.
Female subjects must be surgically sterilized or postmenopausal.
Exclusion Criteria:
Type 1 diabetes or diabetes treated with insulin injection.
Insulin therapy or oral antidiabetic medication other than metformin, sitagliptin, saxagliptin, a sulfonylurea or combination of these.
Sitting blood pressure above 150/95 mmHg on two evaluations at least 10 minutes apart at screening.
Positive results on screen for drugs of abuse.
Previous treatment with an investigational drug within 30 days or 7 half-lives, whichever is longer.
Previous treatment with EGT0001474 or EGT0001442.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mason W Freeman, M.D.
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Research Site #10
City
Birmingham
State/Province
Alabama
Country
United States
Facility Name
Research Site #04
City
National City
State/Province
California
Country
United States
Facility Name
Research Site #12
City
Denver
State/Province
Colorado
Country
United States
Facility Name
Research Site #07
City
Miami
State/Province
Florida
Country
United States
Facility Name
Research Site #08
City
Miami
State/Province
Florida
Country
United States
Facility Name
Research Site #06
City
Reading
State/Province
Pennsylvania
Country
United States
Facility Name
Research Site #11
City
DeSoto
State/Province
Texas
Country
United States
Facility Name
Research Site #01
City
San Antonio
State/Province
Texas
Country
United States
Facility Name
Research Site #15
City
San Antonio
State/Province
Texas
Country
United States
Facility Name
Research Site #03
City
Brampton
State/Province
Ontario
Country
Canada
Facility Name
Research Site #13
City
London
State/Province
Ontario
Country
Canada
Facility Name
Research Site #02
City
Mississauga
State/Province
Ontario
Country
Canada
12. IPD Sharing Statement
Learn more about this trial
Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus
We'll reach out to this number within 24 hrs